Clinical Trial

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-08.
Status change: Not Yet Recruiting → Recruiting 2026-06-16
Trial Details
NCT Number NCT07164170
Lead Sponsor Abbisko Therapeutics Co, Ltd
Conditions Non-Small Cell Lung Cancer
Enrollment 86 participants
Start Date 2025-09-22
Primary Completion 2028-12-30 (estimated)
Study Completion 2029-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-17